References
[1] Wang YY, Lin GJ, Lin GC, et al. Predictive value of six inflammatory immune indicators for the prognosis of patients with liver cancer and portal vein tumor thrombosis treated with TACE combined with apatinib. Zhejiang Med J. 2025;47(15):1626-1631.
[2] Wang J. Effect of immunotherapy combined with targeted therapy in patients with liver cancer and portal vein tumor thrombosis after surgery. J Chin Foreign Med Res. 2025;4(18):55-57.
[3] Ling JM. Analysis of the efficacy and safety of TACE-HAIC-lenvatinib-tislelizumab quadruple therapy in the treatment of liver cancer and portal vein tumor thrombosis [dissertation]. Gannan Medical University; 2025.
[4] Wen XJ. Evaluation of the efficacy of IMRT combined with TACE in the treatment of unresectable hepatocellular carcinoma and portal vein tumor thrombosis and analysis of prognostic factors based on SMI [dissertation]. Gannan Medical University; 2025.
[5] Huang YD, Xiong Q. Clinical value of abdominal ultrasound in the hemodynamic assessment of portal hypertension and portal vein tumor thrombus in patients with primary liver cancer. Chin J Disaster Rescue Med. 2025;12(04):472-475.
[6] Zhong GH, Xu ZQ, Zeng GH, et al. Effect of transradial artery TACE+HAIC combined with immune targeted therapy on patients with postoperative liver cancer and portal vein tumor thrombus. Med Theory Pract. 2024;37(23):4019-4021.
[7] Wang HR, Li HY, Zhang L. Clinical study of radiotherapy combined with chemotherapy in the treatment of liver cancer and portal vein tumor thrombus. J Transl Med. [2025-08-27]. Available from: URL
[8] Wang HR, Li HY, Zhang L. Clinical study of radiotherapy combined with chemotherapy in the treatment of liver cancer and portal vein tumor thrombus. J Transl Med. 2024;13(03):424-426+430.
[9] Wang YY, Lin GJ, Lin GC, et al. The predictive value of six inflammatory immune markers in the prognosis of patients with portal vein tumor thrombus and liver cancer treated with TACE combined with apatinib. Zhejiang Med J. 2025;47(15):1626-1631.
[10] He W, Zha YZ, Cao W. The Impact of Systemic Immune Inflammatory Index on Prognosis in Primary Liver Cancer Patients Treated with Hepatic Artery Chemotherapy Embolization. Clin J Mil Med. 2025;53(08):823-826+830.
[11] Wang J. The application effect of immunotherapy combined with targeted therapy in patients with liver cancer complicated by portal vein tumor thrombus after surgery. Chin Foreign Med Res. 2025;4(18):55-57.
[12] Zhang W, Gao W, Liu C, et al. Donafenib combined with HAIC and sintilimab for the treatment of hepatocellular carcinoma with accompanying inferior vena cava tumor embolism achieving complete remission. Tianjin Med J. 2023;51(02):203-206.
[13] Shi YC. Application of Intensified Radiotherapy Combined with Chemotherapy in Liver Cancer with Venous/Inferior Vena Cava Carcinoma Thrombus. China Pract Med. 2024;19(09):87-90.
[14] Zheng WT, Wen B, Yan QY, et al. Observation on the efficacy of combined radiotherapy and chemotherapy with intensified treatment for liver cancer complicated by portal vein or inferior vena cava tumor thrombus. J Clin Med Eng. 2020;27(05):567-568.
[15] Kimura Y, Tokumitsu Y, Shindo Y, et al. Induction hepatic arterial infusion chemotherapy followed by surgery for hepatocellular carcinoma with massive portal vein tumor thrombosis: a case series of 20 patients. J Med Case Rep. 2025;19(1):218.
[16] Sahai P, Yadav PH, Choudhury A, et al. Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis. BJR Open. 2025;7(1):tzaf002.
[17] Krishnamurthy R, Cherry D, Russo RC, et al. Concurrent Radiation and Immunotherapy for Unresectable Hepatocellular Carci-noma with Portal Vein Thrombus. Int J Radiat Oncol Biol Phys. 2024;120(2S):e456-e457.
[18] Katarzyna M, Joanna L, Tomasz G, et al. Simultaneous surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava and ischemic heart disease own research and literature review. Pol Przegl Chir. 2022;95(1):33-38.
[19] Matteo S, Alberta C, Alessandro C, et al. Deceased donor liver transplantation after radioembolization for hepatocellular carcino-ma and portal vein tumoral thrombosis: a pilot study. Liver Transpl. 2021;27(12):1758-1766.
[20] Chung C, Mitry M, Joshi M, et al. Abstract No. 544 Locoregional therapies versus systemic therapy for hepatocellular carcinoma with portal vein tumor thrombus. J Vasc Interv Radiol. 2020;31(3):S238.